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Purpose/Objective: Despite significant research input aiming 
to improve therapy regimens, rectal cancer remains as one of 
the cancers with significant morbidity rates. Radiotherapy 
has been shown to lower 10-year local recurrence by 
approximately 50%. A substantial number of rectal tumours 
fail to respond to radiotherapy which not only presents a 
barrier for effective cancer treatment bu also means that 
those patients with therapy resistant tumours endure the 
harmful side effects of radiotherapy for no therapeutic gain. 
Therefore, it is important to identify biomarkers capable of 
predicting a tumour's response to radiotherapy prior to 
treatment which can improve therapy outcomes. The aim of 
this study is to identify putative protein biomarkers of 
radiotherapy resistance using rectal cancer tissue biopsy 
samples by employing comparative proteomic tools. Ultimate 
aim is to translate these biomarkers into an assay panel for 
routine cancer screening aiding the personalisation of cancer 
treatment. 
Materials and Methods: Following ethical approval (Sheffield 
REC ref 10/H1308/37), two pairs of pre-treatment rectal 
cancer biopsy samples (radioresistant versus radiosensitive) 
were investigated using antibody microarray to identify 
differentially expressed proteins (DEPs) involved in mediating 
radiotherapy resistance. Data obtained from the experiments 
were subjected to data mining using Ingenuity Pathway 
Analysis (IPA) which mapped these DEPs onto their most 
relevant canonical signalling pathways. 
Results: The antibody microarray analysis of the clinical 
samples revealed 25 DEPs and 46 DEPs from the first and the 
second experiment, respectively. The IPA analysis of these 
combined generated 253 canonical pathways. Amongst these, 
the most interesting pathways included p53 signalling (12 
DEPs mapped), death receptor signalling (7 DEPs mapped), 
apoptosis signalling (5 DEPs mapped) and EGF signalling (4 
DEPs mapped). Radiotherapy is known to initiate cellular 
apoptosis via the intrinsic (mitochondrial) apoptotic pathway. 
However, the identification of some regulatory proteins 
involved in the extrinsic pathway (death receptor) apoptotic 
pathway (Figure 1) has revealed a potential link between 
radiotherapy and this pathway. 
 
 
Figure 1: Death Receptor Signalling 
 
A total of 7 DEPs were mapped onto the Death Receptor 
Signalling pathway, namely CRADD, TNFRSF25, MAPK8, 
TNFSF10, NFKB1, TNFRSF10A and TNF. 
Conclusions: Antibody microarray analysis of rectal cancer 
biopsy samples has enabled the identification of a number of 
DEPs which may be involved in mediating response to 
radiotherapy. However, further confirmation with western 
blotting and validation with immunohistochemistry are 
required before such biomarkers can be introduced into 
routine clinical management of cancer patients.  
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Purpose/Objective: The risk of local recurrence, metastases 
and overall survival of locally advanced rectal cancer after 
preoperative chemoradiation and curative surgery can be 
estimated by prediction models and visualized using 
nomograms, which have been trained and validated in 
European clinical trial populations. This study aims to 
validate these prediction models in a routine clinical Chinese 
cohort. 
Materials and Methods: From 2006 to 2012, clinical data of 
277 consecutive locally advanced rectal adenocarcinoma 
patients treated with preoperative chemoradiation and 
curative surgery from a single Chinese Cancer Center, were 
retrospectively collected and used for external validation. 
Concordance index (C-index) and calibration curves were 
used to assess the performance of the previously developed 
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prediction models in this routine clinical validation 
population. 
Results: The C-index for the published prediction models was 
0.72, 0.75 and 0.72 in predicting 2-year local recurrence 
(LR), distant metastases (DM) and overall survival (OS) in the 
Chinese population, respectively. Kaplan-Meier curves 
indicated good discriminating performance of local control, 
however, couldn’t discriminate a low-risk and medium-risk 
group well for distant control and overall survival. Calibration 
curves showed a trend of underestimation of local and 
distant control, as well as overall survival in the observed 
data compared with the model predicted one. 
Conclusions: We externally validated three models for 
predicting 2-year LR, DM and OS of locally advanced rectal 
cancer patients who underwent preoperative chemoradiation 
and curative surgery with good discrimination in a single 
Chinese cohort, however the model overestimated the local 
control rate compared to observations in the clinical cohort. 
Furthermore, validation in other clinical routine cohorts and 
optimization of the prediction model including additional 
prognostic factors will enhance model validity and enhance 
applicability for personalized treatment of locally advanced 
rectal cancer. 
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Purpose/Objective: This study is to report initial clinical 
response of hepatocellular carcinoma (HCC) treated with 
dynamic tumor-tracking stereotactic body radiotherapy (DTT-
SBRT) with real-time monitoring using the Vero4DRT system. 
Materials and Methods: Eligibility criteria for this study were 
(1) one liver tumor with a diameter of 50mm or less, (2) 
technical difficulties for ablation therapies, inoperable, (3) 
performance status of 0-2, (4) Child-Pugh score of 8 or less, 
and (5) respiratory motion of 10mm or more. A fiducial 
marker (Visicoil) was placed near the tumor percutaneously 
under ultrasonographic guidance in advance. Internal target 
volume (ITV) for tracking was defined on the end-exhale 
phase of a 4DCT set. The ITV was delineated to compensate 
tumor-marker variation during respiration. Planning target 
volume (PTV) margin was defined for each patient taking 
some factors into account: interfraction variation of positions 
between the tumor and Visicoil, 4D modeling error, baseline 
drift of the abdominal wall movement, and mechanical error 
of the Vero4DRT. 
Between August 2013 and August 2014, nine patients were 
included in this study. Three were male and six were female. 
A median age was 79 years old with the range from 68 to 88. 
A median tumor diameter was 30 mm with the range from 8 
mm to 50 mm. In the Child-Pugh classification, five patients 
were classified to the Child-Pugh A, and others were 
classifies to B. Six patients were treated with 48 Gy in four 
fractions and others with tumor near digestive tract were 
treated with 56 Gy in eight fractions at isocenter by using 6-
MV photon beam. 
Results: DTT-SBRT was performed successfully. In contrast-
enhancement CT or MRI after 3 months or more from DTT-
SBRT, early arterial enhancement of HCC disappeared in 
eight patients. The other one had still early arterial 
enhancement in the tumor but this enhancement area was 
decreased at 45 days later from DTT-SBRT. All patients were 
classified to the same Child-Pugh criteria. No grade 2 or more 
adverse effect was noted. Two patients had a new HCC 
outside irradiation field. 
Conclusions: DTT-SBRT with real-time monitoring using 
Vero4DRT system seemed to be effective in the treatment of 
HCC. DTT-SBRT has the possibility of alternative method in 
the treatment of HCC. 
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Purpose/Objective: We evaluated the outcomes of adjuvant 
chemoradiotherapy (CRT) following local excision in patients 
diagnosed as early rectal cancer. 
Materials and Methods: Eighty five patients who had 
completed postoperative adjuvant CRT after local excision of 
early rectal cancer were included in this analysis. All patients 
were pathologically confirmed as stage T1 or stage T2 rectal 
cancer after local excision. The radiation dose ranged from 
39.6 Gy ~ 59.4 Gy (median; 50.4), given in 1.8 Gy fractions 
over 4 or 7 weeks. A concurrent chemotherapy regimen of 
fluorouracil (425 mg/m2/day) and leucovorin (20 mg/m2/day) 
was administered for 4 days during week 1 and 5 of 
radiotherapy except 2 patients (2.4 %) who refused 
chemotherapy. 
Results: Seventeen patients (20 %) showed pathologic stage 
T2 and 20 patients (23.5 %) showed resection margin of less 
than 3 mm. The median duration of follow-up was 49 months. 
The median survival was not reached. The 5-year overall 
survival, locoregional relapse-free survival, and disease-free 
survival rate for all 85 patients were 96.8 %, 92.3 %, and 91.3 
%, respectively. The patients with pathologic T2 stage (p = 
0.004) or resection margin < 3 mm (p = 0.006) showed worse 
disease-free survival in multivariate analysis. In thirty-four 
patients with pathologic T2 stage and/or resection margin < 3 
mm, four patients who received radiotherapy of 54.0 Gy did 
not develop any recurrence, while 3 out of 30 patients (10.0 
%) of equal or less than 50.4 Gy developed local failure. 
Conclusions: Postoperative CRT following local excision in 
patients with early rectal cancer could be effective adjuvant 
treatment without revision radical surgery. However, we 
recommend that radiotherapy dose of 54.0 Gy might be 
necessary to achieve better local control in the patients with 
pathologic T2 stage and/or resection margin < 3 mm.  
